New research paper shows that AstraZeneca has achieved greater than four-fold improvement in R&D productivity

AstraZenecaIn a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity following significant revision of its approach and adoption of a '5R framework' - right target, right patient, right tissue, right safety, right commercial potential.

The publication explains how adoption of the research unit's 5R framework has guided successful, efficient drug discovery and development whilst financial investment in R&D has remained unchanged. It shows that the research unit’s success rate in discovering new compounds, which then progress through the pipeline to completion of Phase III clinical trials, has increased from 4% in the period 2005-2010 to 19% in the period 2012-2016 based on the 5R framework.

The improvement positions R&D productivity above the pharmaceutical industry average of 6% for small molecules in the 2013-2015 timeframe(2). The transformation accompanied a strategic re-focusing on three main therapy areas: Oncology, Cardiovascular & Metabolic Diseases and Respiratory.

Mene Pangalos, Executive Vice President, IMED Biotech Unit and Business Development, said: "In a high-risk industry facing a well-documented decline in productivity2, I am proud to see the impact of our 5R strategy on our R&D success. There is still room for improvement, but we expect the focus on scientific rigour to further enhance our capability for translating science into innovative medicines for patients."

The IMED Biotech Unit’s 5R framework focuses on quality rather than quantity at all stages of drug discovery and development. Hence, the number of projects in discovery has decreased while their likelihood of success has increased. Other key factors include investment in state-of-the-art technologies, such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and next-generation sequencing, to produce better quality drug candidates for development, as well as a change in culture to focus on the science rather than the commercial opportunity.

Components of the increased R&D productivity include:

  • Early identification of patients most likely to benefit from treatment led to 62% of projects progressing to the next phase of development compared with 46% without prospective patient selection. Today, >90% of projects in the IMED Biotech Unit pipeline have a patient selection approach.
  • Progression to Phase III trials maintained at 2010 levels despite 50% lower number of candidate drugs in development.
  • Greater than four-fold reduction in preclinical project safety due to adoption of best practice predictive and translational science.
  • 70% of projects where proof-of-mechanism (POM) was demonstrated were associated with increased clinical success compared with 26% where POM was not demonstrated. In the 2005-2010 pipeline cohort fewer than 5 projects demonstrated POM compared with 29 in the 2012-2016 cohort. POM is a demonstration that a new compound reaches its target organ(s), interacts with its molecular target, and affects the biology of the target cells as intended.

The increased R&D productivity is mirrored by a substantial rise in the number of peer-reviewed research publications published by the IMED Biotech Unit’s scientists, especially in high-impact journals.

About IMED Biotech Unit

IMED Biotech Unit is one of two global research and early development arms of AstraZeneca, focusing on advancing small molecules, oligonucleotides and other emerging technologies and drug discovery platforms. The Biotech Unit conducts innovative discovery research and early-stage development from initial target selection to Phase II trial completion.

The second global research and early development arm is MedImmune which is responsible for global biologics R&D, including immunotherapies.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

1. Morgan P, Brown DG, Lennard S, Anderton M, Barett JC, Eriksson U, Fidock M, Hamren B, Johnson A, March RE, Matcham J, Mettetal J, Nichols DJ, Platz S, Rees S, Snowden MA, Pangalos MN. (2011) Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery (In Press).
2. Data sourced from CMR International’s 2016 Global R&D Performance Metrics Programme)

Most Popular Now

FDA grants priority review to Roche's cancer immun…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) a...

Kymriah® (tisagenlecleucel), first-in-class CAR-T …

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication ...

Daily aspirin linked to higher risk in men

Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. W...

New leads on treating dementia and Alzheimer's

A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to ca...

Roche reports a strong start in 2018

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division in...

To treat pain, you need to treat the patient

People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depr...

Novo Nordisk participates in new research project …

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find bet...

Chemical octopus catches sneaky cancer clues, trac…

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until n...

Alcon Cares Project 100 commits to reducing catara…

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to ...

FDA approves novel preventive treatment for migrai…

The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly se...

First clues to the causes of multiple sclerosis

Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision...

Doctors in US and Canada launch sweeping pharmaceu…

The skyrocketing cost of prescription drugs is one of the biggest concerns for American voters. However, in his proposal last Friday, President Donald Trump failed to off...